<?xml version='1.0' encoding='utf-8'?>
<document id="28232141"><sentence text="Pharmacokinetic drug-drug interaction between erlotinib and paracetamol: A potential risk for clinical practice."><entity charOffset="46-55" id="DDI-PubMed.28232141.s1.e0" text="erlotinib" /><entity charOffset="60-71" id="DDI-PubMed.28232141.s1.e1" text="paracetamol" /><pair ddi="false" e1="DDI-PubMed.28232141.s1.e0" e2="DDI-PubMed.28232141.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28232141.s1.e0" e2="DDI-PubMed.28232141.s1.e1" /></sentence><sentence text="Erlotinib is a tyrosine kinase inhibitor available for the treatment of non-small cell lung cancer"><entity charOffset="0-9" id="DDI-PubMed.28232141.s2.e0" text="Erlotinib" /><entity charOffset="15-23" id="DDI-PubMed.28232141.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.28232141.s2.e0" e2="DDI-PubMed.28232141.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28232141.s2.e0" e2="DDI-PubMed.28232141.s2.e1" /></sentence><sentence text=" Paracetamol is an analgesic agent, commonly used in cancer patients"><entity charOffset="1-12" id="DDI-PubMed.28232141.s3.e0" text="Paracetamol" /></sentence><sentence text=" Because these drugs are often co-administered, there is an increasing issue of interaction between them" /><sentence text="" /><sentence text="The aim of the study was to investigate the effect of paracetamol on the pharmacokinetic parameters of erlotinib, as well as the influence of erlotinib on the pharmacokinetics of paracetamol"><entity charOffset="54-65" id="DDI-PubMed.28232141.s6.e0" text="paracetamol" /><entity charOffset="103-112" id="DDI-PubMed.28232141.s6.e1" text="erlotinib" /><entity charOffset="142-151" id="DDI-PubMed.28232141.s6.e2" text="erlotinib" /><entity charOffset="179-190" id="DDI-PubMed.28232141.s6.e3" text="paracetamol" /><pair ddi="false" e1="DDI-PubMed.28232141.s6.e0" e2="DDI-PubMed.28232141.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28232141.s6.e0" e2="DDI-PubMed.28232141.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28232141.s6.e0" e2="DDI-PubMed.28232141.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28232141.s6.e0" e2="DDI-PubMed.28232141.s6.e3" /><pair ddi="false" e1="DDI-PubMed.28232141.s6.e1" e2="DDI-PubMed.28232141.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28232141.s6.e1" e2="DDI-PubMed.28232141.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28232141.s6.e1" e2="DDI-PubMed.28232141.s6.e3" /><pair ddi="false" e1="DDI-PubMed.28232141.s6.e2" e2="DDI-PubMed.28232141.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28232141.s6.e2" e2="DDI-PubMed.28232141.s6.e3" /></sentence><sentence text="" /><sentence text="The rabbits were divided into three groups: the rabbits receiving erlotinib (IER), the group receiving paracetamol (IIPR), and the rabbits receiving erlotinib+paracetamol (IIIER+PR)"><entity charOffset="66-75" id="DDI-PubMed.28232141.s8.e0" text="erlotinib" /><entity charOffset="77-80" id="DDI-PubMed.28232141.s8.e1" text="IER" /><entity charOffset="103-114" id="DDI-PubMed.28232141.s8.e2" text="paracetamol" /><entity charOffset="116-120" id="DDI-PubMed.28232141.s8.e3" text="IIPR" /><entity charOffset="149-170" id="DDI-PubMed.28232141.s8.e4" text="erlotinib+paracetamol" /><entity charOffset="174-194" id="DDI-PubMed.28232141.s8.e5" text="IER" /><pair ddi="false" e1="DDI-PubMed.28232141.s8.e0" e2="DDI-PubMed.28232141.s8.e0" /><pair ddi="false" e1="DDI-PubMed.28232141.s8.e0" e2="DDI-PubMed.28232141.s8.e1" /><pair ddi="false" e1="DDI-PubMed.28232141.s8.e0" e2="DDI-PubMed.28232141.s8.e2" /><pair ddi="false" e1="DDI-PubMed.28232141.s8.e0" e2="DDI-PubMed.28232141.s8.e3" /><pair ddi="false" e1="DDI-PubMed.28232141.s8.e0" e2="DDI-PubMed.28232141.s8.e4" /><pair ddi="false" e1="DDI-PubMed.28232141.s8.e0" e2="DDI-PubMed.28232141.s8.e5" /><pair ddi="false" e1="DDI-PubMed.28232141.s8.e1" e2="DDI-PubMed.28232141.s8.e1" /><pair ddi="false" e1="DDI-PubMed.28232141.s8.e1" e2="DDI-PubMed.28232141.s8.e2" /><pair ddi="false" e1="DDI-PubMed.28232141.s8.e1" e2="DDI-PubMed.28232141.s8.e3" /><pair ddi="false" e1="DDI-PubMed.28232141.s8.e1" e2="DDI-PubMed.28232141.s8.e4" /><pair ddi="false" e1="DDI-PubMed.28232141.s8.e1" e2="DDI-PubMed.28232141.s8.e5" /><pair ddi="false" e1="DDI-PubMed.28232141.s8.e2" e2="DDI-PubMed.28232141.s8.e2" /><pair ddi="false" e1="DDI-PubMed.28232141.s8.e2" e2="DDI-PubMed.28232141.s8.e3" /><pair ddi="false" e1="DDI-PubMed.28232141.s8.e2" e2="DDI-PubMed.28232141.s8.e4" /><pair ddi="false" e1="DDI-PubMed.28232141.s8.e2" e2="DDI-PubMed.28232141.s8.e5" /><pair ddi="false" e1="DDI-PubMed.28232141.s8.e3" e2="DDI-PubMed.28232141.s8.e3" /><pair ddi="false" e1="DDI-PubMed.28232141.s8.e3" e2="DDI-PubMed.28232141.s8.e4" /><pair ddi="false" e1="DDI-PubMed.28232141.s8.e3" e2="DDI-PubMed.28232141.s8.e5" /><pair ddi="false" e1="DDI-PubMed.28232141.s8.e4" e2="DDI-PubMed.28232141.s8.e4" /><pair ddi="false" e1="DDI-PubMed.28232141.s8.e4" e2="DDI-PubMed.28232141.s8.e5" /></sentence><sentence text=" A single dose of erlotinib was administered orally (25mg) and was administered intravenously (35mg/kg)"><entity charOffset="18-27" id="DDI-PubMed.28232141.s9.e0" text="erlotinib" /></sentence><sentence text=" Plasma concentrations of erlotinib, its metabolite (OSI420), paracetamol and its metabolites - glucuronide and sulphate were measured with the validated method"><entity charOffset="26-35" id="DDI-PubMed.28232141.s10.e0" text="erlotinib" /><entity charOffset="62-73" id="DDI-PubMed.28232141.s10.e1" text="paracetamol" /><entity charOffset="112-120" id="DDI-PubMed.28232141.s10.e2" text="sulphate" /><pair ddi="false" e1="DDI-PubMed.28232141.s10.e0" e2="DDI-PubMed.28232141.s10.e0" /><pair ddi="false" e1="DDI-PubMed.28232141.s10.e0" e2="DDI-PubMed.28232141.s10.e1" /><pair ddi="false" e1="DDI-PubMed.28232141.s10.e0" e2="DDI-PubMed.28232141.s10.e2" /><pair ddi="false" e1="DDI-PubMed.28232141.s10.e1" e2="DDI-PubMed.28232141.s10.e1" /><pair ddi="false" e1="DDI-PubMed.28232141.s10.e1" e2="DDI-PubMed.28232141.s10.e2" /></sentence><sentence text="" /><sentence text="During paracetamol co-administration we observed increased erlotinib maximum concentration (Cmax) and area under the plasma concentration-time curve from time zero to infinity (AUC0-∞) by 87"><entity charOffset="7-18" id="DDI-PubMed.28232141.s12.e0" text="paracetamol" /><entity charOffset="59-68" id="DDI-PubMed.28232141.s12.e1" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.28232141.s12.e0" e2="DDI-PubMed.28232141.s12.e0" /><pair ddi="false" e1="DDI-PubMed.28232141.s12.e0" e2="DDI-PubMed.28232141.s12.e1" /></sentence><sentence text="7% and 31" /><sentence text="1%, respectively" /><sentence text=" In turn, erlotinib lead to decreased paracetamol AUC0-∞ by 35"><entity charOffset="38-49" id="DDI-PubMed.28232141.s15.e0" text="paracetamol" /></sentence><sentence text="5% and Cmax by 18" /><sentence text="9%" /><sentence text=" The mean values of paracetamol glucuronide/paracetamol ratios for Cmax were 32"><entity charOffset="20-43" id="DDI-PubMed.28232141.s18.e0" text="paracetamol glucuronide" /><entity charOffset="44-55" id="DDI-PubMed.28232141.s18.e1" text="paracetamol" /><pair ddi="false" e1="DDI-PubMed.28232141.s18.e0" e2="DDI-PubMed.28232141.s18.e0" /><pair ddi="false" e1="DDI-PubMed.28232141.s18.e0" e2="DDI-PubMed.28232141.s18.e1" /></sentence><sentence text="2% higher, whereas paracetamol sulphate/paracetamol ratios for Cmax and AUC0-∞ were 37"><entity charOffset="19-39" id="DDI-PubMed.28232141.s19.e0" text="paracetamol sulphate" /><entity charOffset="40-51" id="DDI-PubMed.28232141.s19.e1" text="paracetamol" /><pair ddi="false" e1="DDI-PubMed.28232141.s19.e0" e2="DDI-PubMed.28232141.s19.e0" /><pair ddi="false" e1="DDI-PubMed.28232141.s19.e0" e2="DDI-PubMed.28232141.s19.e1" /></sentence><sentence text="1% and 57" /><sentence text="1% lower in the IIPR group, when compared to the IIIER+PR group"><entity charOffset="49-57" id="DDI-PubMed.28232141.s21.e0" text="IIIER+PR" /><entity charOffset="51-58" id="DDI-PubMed.28232141.s21.e1" text="IER" /><entity charOffset="16-23" id="DDI-PubMed.28232141.s21.e2" text="IIPR" /><pair ddi="false" e1="DDI-PubMed.28232141.s21.e2" e2="DDI-PubMed.28232141.s21.e2" /><pair ddi="false" e1="DDI-PubMed.28232141.s21.e2" e2="DDI-PubMed.28232141.s21.e0" /><pair ddi="false" e1="DDI-PubMed.28232141.s21.e2" e2="DDI-PubMed.28232141.s21.e1" /><pair ddi="false" e1="DDI-PubMed.28232141.s21.e0" e2="DDI-PubMed.28232141.s21.e0" /><pair ddi="false" e1="DDI-PubMed.28232141.s21.e0" e2="DDI-PubMed.28232141.s21.e1" /></sentence><sentence text="" /><sentence text="Paracetamol had significant effect on the enhanced plasma exposure of erlotinib"><entity charOffset="0-11" id="DDI-PubMed.28232141.s23.e0" text="Paracetamol" /><entity charOffset="70-79" id="DDI-PubMed.28232141.s23.e1" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.28232141.s23.e0" e2="DDI-PubMed.28232141.s23.e0" /><pair ddi="false" e1="DDI-PubMed.28232141.s23.e0" e2="DDI-PubMed.28232141.s23.e1" /></sentence><sentence text=" Additionally, erlotinib contributed to the lower concentrations of paracetamol"><entity charOffset="15-24" id="DDI-PubMed.28232141.s24.e0" text="erlotinib" /><entity charOffset="68-79" id="DDI-PubMed.28232141.s24.e1" text="paracetamol" /><pair ddi="false" e1="DDI-PubMed.28232141.s24.e0" e2="DDI-PubMed.28232141.s24.e0" /><pair ddi="false" e1="DDI-PubMed.28232141.s24.e0" e2="DDI-PubMed.28232141.s24.e1" /></sentence><sentence text=" Decreased glucuronidation and increased sulphation of paracetamol after co-administration of erlotinib were also observed"><entity charOffset="55-66" id="DDI-PubMed.28232141.s25.e0" text="paracetamol" /><entity charOffset="94-103" id="DDI-PubMed.28232141.s25.e1" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.28232141.s25.e0" e2="DDI-PubMed.28232141.s25.e0" /><pair ddi="false" e1="DDI-PubMed.28232141.s25.e0" e2="DDI-PubMed.28232141.s25.e1" /></sentence><sentence text="" /></document>